Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

RCT (n=336) found atezolizumab combined with bevacizumab resulted in better overall (67.2% vs. 54.6% at 12 months; HR for death 0.58; 95% CI, 0.42-0.79; p<0.001) and progression-free (6.8 vs. 4.3 months; HR 0.59; 95% CI, 0.47 to 0.76; p<0.001) survival outcomes than sorafenib.

Source:

New England Journal of Medicine